Results of the first international quality control programme for oral targeted oncolytics

Abstract

AimsWith the rising number of oral targeted oncolytics and growing awareness of the benefits of therapeutic drug monitoring (TDM) within the field of oncology, it is expected that the requests for quantifying concentrations of these drugs will increase. It is important to (cross‐)validate available assays and ensure its quality, as results may lead to altered dosing recommendations. Therefore, we aimed to evaluate the performance of laboratories measuring concentrations of targeted oral oncolytics in a one‐time international quality control (QC) programme.MethodsParticipating laboratories received a set of plasma samples containing low, medium and high concentrations of imatinib, sunitinib, desethylsunitinib, pazopanib, cabozantinib, olaparib, enzalutamide, desmethylenzalutamide and abiraterone, with the request to report their results back within five weeks after shipment. Accuracy was defined acceptable if measurements where within 85%–115% from the weighed‐in reference concentrations. Besides descriptive statistics, an exploratory ANOVA was performed.ResultsSeventeen laboratories from six countries reported 243 results. Overall, 80.7% of all measurements were within the predefined range of acceptable accuracy. Laboratories performed best in quantifying imatinib and poorest in quantifying desethylsunitinib (median absolute inaccuracy respectively 4.0% (interquartile range (IQR) 1.8%–6.5%) and 15.5% (IQR 8.8%–34.9%)). The poorest performance of desethylsunitinib might be caused by using the stable‐isotope‐labelled sunitinib instead of desethylsunitinib as an internal standard, or due to the light‐induced cis(Z)/trans(E) isomerization of (desethyl)sunitinib. Overall, drug substance and performing laboratory seemed to influence the absolute inaccuracy (F = 16.4; p < 0.001 and F = 35.5; p < 0.001, respectively).ConclusionConsidering this is the first evaluation of an international QC programme for oral targeted oncolytics, an impressive high percentage of measurements were within the predefined range of accuracy. Cross‐validation of assays that are used for dose optimization of oncolytics will secure the performance and will protect patients from incorrect advices.